Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.01
-0.28 (-1.45%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Monte Rosa Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 123.67 | 75.62 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 63.54% | - | - | - | - | Upgrade
|
| Cost of Revenue | 133.7 | 112.86 | 103.37 | - | - | Upgrade
|
| Gross Profit | -10.03 | -37.24 | -103.37 | - | - | Upgrade
|
| Selling, General & Admin | 44.18 | 43.87 | 39.94 | 35.12 | 15.73 | Upgrade
|
| Research & Development | - | - | - | 77.26 | 57.16 | Upgrade
|
| Operating Expenses | 44.18 | 43.87 | 39.94 | 112.38 | 72.88 | Upgrade
|
| Operating Income | -54.21 | -81.11 | -143.31 | -112.38 | -72.88 | Upgrade
|
| Interest & Investment Income | 12.94 | 10.57 | 9.33 | 3.76 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.48 | 0.42 | -0.93 | 0.01 | -0.16 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -0.96 | Upgrade
|
| EBT Excluding Unusual Items | -39.78 | -70.13 | -134.91 | -108.61 | -73.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.13 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.06 | - | 0.02 | 0.11 | - | Upgrade
|
| Pretax Income | -39.72 | -70.13 | -135.01 | -108.5 | -73.96 | Upgrade
|
| Income Tax Expense | -1.1 | 2.57 | 0.34 | - | - | Upgrade
|
| Net Income | -38.63 | -72.7 | -135.35 | -108.5 | -73.96 | Upgrade
|
| Net Income to Common | -38.63 | -72.7 | -135.35 | -108.5 | -73.96 | Upgrade
|
| Shares Outstanding (Basic) | 83 | 74 | 51 | 47 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 83 | 74 | 51 | 47 | 25 | Upgrade
|
| Shares Change (YoY) | 12.39% | 43.80% | 8.83% | 88.91% | 1548.09% | Upgrade
|
| EPS (Basic) | -0.46 | -0.98 | -2.63 | -2.30 | -2.96 | Upgrade
|
| EPS (Diluted) | -0.46 | -0.98 | -2.63 | -2.30 | -2.96 | Upgrade
|
| Free Cash Flow | -27.5 | 38.01 | -62.84 | -105.38 | -69.1 | Upgrade
|
| Free Cash Flow Per Share | -0.33 | 0.51 | -1.22 | -2.23 | -2.76 | Upgrade
|
| Gross Margin | -8.11% | -49.25% | - | - | - | Upgrade
|
| Operating Margin | -43.83% | -107.26% | - | - | - | Upgrade
|
| Profit Margin | -31.23% | -96.14% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -22.23% | 50.26% | - | - | - | Upgrade
|
| EBITDA | -45.85 | -72.99 | -137.09 | -108.64 | -70.75 | Upgrade
|
| EBITDA Margin | -37.08% | -96.52% | - | - | - | Upgrade
|
| D&A For EBITDA | 8.36 | 8.12 | 6.22 | 3.75 | 2.13 | Upgrade
|
| EBIT | -54.21 | -81.11 | -143.31 | -112.38 | -72.88 | Upgrade
|
| EBIT Margin | -43.83% | -107.26% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.